Table 2 Clinical results: comparative summary of the clinical results relative to the treatment group
CLINICAL OUTCOME | SBRT-PATHY (20 patients) | CHT (20 patients) | PALLIATIVE RT (20 patients) | p-value |
|---|---|---|---|---|
BULKY RESPONSE (CR OR PR) | 95% (19/20) | 20% (4/20) | 20% (4/20) | 0.005 |
DISTANT TUMOR CONTROL | 45% (9/20) (AE) | 55% (11/20) (CHT) | 0% (0/20) (AE) | 0.010 |
OVERALL SURVIVAL at 1 year | 75% (15/20) | 60% (12/20) | 20% (4/20) | 0.099 |
CANCER SPECIFIC SURVIVAL at 1 year | 90% (18/20) | 60% (12/20) | 20% (4/20) | 0.049 |
PROGRESSION FREE SURVIVAL at 1 year | 60% (12/20) | 15% (3/20) | 0% (0/20) | 0.003 |
TOXICITY: | 15% (3/20) | 65% (13/20) | 15% (3/20) | 0.026 |
Fatigue | 3 (15) Grade 1 | 13 (65) Grade 1–3 | 3 (15) Grade 1 | 0.005 |
Dysphagia | 0 (0) | 0 (0) | 2 (10) Grade 1 | 0.126 |
Nausea/Vomiting | 0 (0) | 5 (25) Grade 2 | 0 (0) | 0.004 |
Diarrhea | 0 (0) | 4 (20) Grade 2 | 0 (0) | 0.014 |
Pancytopenia | 0 (0) | 9 (45) Grade 2–3 | 0 (0) | 0.001 |
Leukopenia | 0 (0) | 9 (45) Grade 2–3 | 0 (0) | 0.001 |
Neuropathy | 0 (0) | 3 (15) Grade 1–2 | 0 (0) | 0.042 |
Pneumonitis | 0 (0) | 2 (10) Grade 2 | 0 (0) | 0.126 |
SYMPTOM CONTROL | 80% (16/20) | 15% (3/20) | 25% (5/20) | 0.018 |